Table 1.
Baseline characteristics of the three polycystic ovary syndrome (PCOS) subgroups and control subjects.
| Characteristic | PCOS | Controls | ||
|---|---|---|---|---|
| NOIR | NIR | OIR | ||
| Number | 34 | 32 | 41 | 37 |
| Age (years) | 27.88 (26.30–29.46) | 28.05 (26.96–29.14) | 26.97 (25.56–28.38) | 28.11 (26.33–29.89) |
| BMI (kg/m2) | 21.03 (20.51–21.56) | 20.06 (19.55–20.56) | 28.05 (27.02–29.07)* | 20.98 (20.15–21.81) |
| WHR | 0.83 (0.81–0.85)* | 0.80 (0.78–0.81) | 0.88 (0.86–0.90)* | 0.79 (0.78–0.80) |
| HOMA-IR | 3.25 (3.01–3.48)* | 1.19 (1.10–1.29) | 4.85 (3.99–5.71)* | 1.04 (0.95–1.14) |
| CHOL (mg/dl) | 5.00 (4.74–5.25)* | 4.38 (4.10–4.67) | 5.28 (4.90–5.66)* | 4.38 (4.17–4.58) |
| TG (mg/dl) | 1.30 (1.10–1.49)* | 0.74 (0.68–0.81) | 2.08 (1.39–2.77)* | 0.78 (0.68–0.88) |
| HDL (mg/dl) | 1.33 (1.23–1.42) | 1.51 (1.40–1.61) | 1.19 (1.12–1.27)* | 1.43 (1.34–1.51) |
| LDL (mg/dl) | 3.18 (2.96–3.39)* | 2.61 (2.45–2.77) | 3.34 (3.08–3.60)* | 2.59 (2.44–2.73) |
| LH (mIU/ml) | 9.61 (7.78–11.44)* | 9.83 (7.66–12.00)* | 8.71 (7.42–10.00)* | 4.63 (4.08–5.19) |
| LH/FSH | 1.60 (1.32–1.89)* | 1.41 (1.10–1.71)* | 1.56 (1.34–1.78)* | 0.67 (0.58–0.76) |
| TT (ng/ml) | 0.64 (0.55–0.72)* | 0.60 (0.53–0.67)* | 0.64 (0.57–0.72)* | 0.42 (0.37–0.47) |
Notes: Data are presented as the mean and (95% confidence interval). Differences in continuous variables among groups were analyzed by ANOVA or Kruskal–Wallis test. *p < 0.05.
Abbreviations: NOIR, non-obesity with insulin resistance; OIR, obesity with insulin resistance; NIR, non-obesity and non-insulin resistance; BMI, body mass index; WHR, waist-to-hip ratio; HOMA-IR, homeostasis model assessment of insulin resistance; CHOL, total cholesterol; TG, triglycerides; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LH, luteinizing hormone; FSH, follicle-stimulating hormone; TT, total testosterone.